ATE205092T1 - Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe - Google Patents

Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe

Info

Publication number: ATE205092T1
Authority: AT; Austria
Prior art keywords: optionally substituted; derivative; highly water; soluble cyclodextrin; group
Prior art date: 1992-01-30

Application number

AT93101237T

Other languages

English (en)

Inventor

Yoshihiro Ohmachi

Yoshihiro Tsugawa

Akihiro Nagai

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-30

Filing date

1993-01-28

Publication date

2001-09-15

1993-01-28 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

2001-09-15 Application granted granted Critical

2001-09-15 Publication of ATE205092T1 publication Critical patent/ATE205092T1/de

Links

HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 6
238000004519 manufacturing process Methods 0.000 title abstract 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 2
150000003839 salts Chemical class 0.000 abstract 4
150000002284 fumagillol derivatives Chemical class 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
229910052717 sulfur Chemical group 0.000 abstract 2
125000006020 2-methyl-1-propenyl group Chemical group 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
150000001450 anions Chemical class 0.000 abstract 1
239000007864 aqueous solution Substances 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
238000002347 injection Methods 0.000 abstract 1
239000007924 injection Substances 0.000 abstract 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
238000003860 storage Methods 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1
125000004434 sulfur atom Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nanotechnology (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Molecular Biology (AREA)
Crystallography & Structural Chemistry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicinal Preparation (AREA)

AT93101237T 1992-01-30 1993-01-28 Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe ATE205092T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP1523692		1992-01-30
JP33202192		1992-12-11

Publications (1)

Publication Number	Publication Date
ATE205092T1 true ATE205092T1 (de)	2001-09-15

Family

ID=26351355

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93101237T ATE205092T1 (de)	1992-01-30	1993-01-28	Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe

Country Status (5)

Country	Link
US (1)	US5536623A (de)
EP (1)	EP0555693B1 (de)
AT (1)	ATE205092T1 (de)
CA (1)	CA2088428A1 (de)
DE (1)	DE69330690T2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2210600A1 (en) *	1996-07-17	1998-01-17	Takashi Houkan	Inhibitor of tumor metastasis or recurrence
KR100357542B1 (ko) *	1998-05-15	2002-10-18	주식회사종근당	푸마질롤 유도체 및 그 제조방법
KR100357541B1 (ko) *	1998-05-15	2002-10-18	주식회사종근당	5-데메톡시 푸마질롤 유도체 및 그 제조방법
JP4922507B2 (ja) *	2000-08-10	2012-04-25	武田薬品工業株式会社	医薬組成物
EP1310248A4 (de)	2000-08-10	2008-05-21	Takeda Pharmaceutical	Pharmazeutische zusammenstellung
KR100451485B1 (ko) *	2002-03-28	2004-10-06	주식회사종근당	푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
CA2731020A1 (en) *	2008-07-18	2010-01-21	Zafgen, Inc.	Use of antiangiogenic fumagillins in the treatment of obesity
WO2013055385A2 (en)	2011-10-03	2013-04-18	Zafgen Corporation	Methods of treating age related disorders
US8642650B2 (en)	2008-12-04	2014-02-04	Zafgen, Inc.	Methods of treating an overweight or obese subject
US20120004162A1 (en)	2008-12-04	2012-01-05	Vath James E	Methods of Treating an Overweight or Obese Subject
MX337575B (es)	2009-10-09	2016-03-10	Zafgen Corp	Compuestos de sulfona y métodos para lafabricación y uso de éstos.
US8815309B2 (en)	2010-01-08	2014-08-26	Zafgen, Inc.	Methods of treating a subject with benign prostate hyperplasia
JP5827239B2 (ja)	2010-01-08	2015-12-02	ザフゲン，インコーポレイテッド	フマギロール型化合物並びにその製造方法及び使用方法
US20130266578A1 (en)	2010-04-07	2013-10-10	Thomas E. Hughes	Methods of treating an overweight subject
AU2011281037B2 (en)	2010-07-22	2014-11-27	Zafgen, Inc.	Tricyclic compounds and methods of making and using same
PH12013500934A1 (en)	2010-11-09	2022-10-24	Zafgen Inc	Crystalline solids of a metap-2 inhibitor and methods of making and using same
AU2011336785A1 (en)	2010-11-29	2013-06-20	Zafgen, Inc	Treatment of obesity using non-daily administration of 6-0-(4 - dimethylaminoethoxy) cinnamoyl fumagillol
WO2012103333A1 (en)	2011-01-26	2012-08-02	Zafgen Corporation	Tetrazole compounds and methods of making and using same
KR101875988B1 (ko)	2011-03-08	2018-07-06	자프겐 인크.	옥사스피로[2.5]옥탄 유도체 및 유사체
SG194812A1 (en)	2011-05-06	2013-12-30	Zafgen Inc	Partially saturated tricyclic compounds and methods of making and using same
US9242997B2 (en)	2011-05-06	2016-01-26	Zafgen, Inc.	Tricyclic pyrazole sulphonamide compunds and methods of making and using same
CN103748094B (zh)	2011-05-06	2016-06-29	扎夫根股份有限公司	三环磺酰胺化合物及其制备和使用方法
BR112014017673A8 (pt)	2012-01-18	2017-07-11	Zafgen Inc	Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
WO2013109735A1 (en)	2012-01-18	2013-07-25	Zafgen, Inc.	Tricyclic sulfone compounds and methods of making and using same
WO2013169727A1 (en)	2012-05-07	2013-11-14	Zafgen, Inc.	Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
EP2846792B1 (de)	2012-05-08	2018-08-15	Zafgen, Inc.	Behandlung von hypothalamischer fettsucht mit metap2-inhibitoren
WO2013169860A1 (en)	2012-05-09	2013-11-14	Zafgen, Inc.	Fumigillol type compounds and methods of making and using same
BR112015010196A2 (pt)	2012-11-05	2017-07-11	Zafgen Inc	métodos de tratar doença do fígado
KR20150079952A (ko)	2012-11-05	2015-07-08	자프겐 인크.	트리시클릭 화합물 및 그의 제조 및 사용 방법
MX2015005733A (es)	2012-11-05	2016-02-10	Zafgen Inc	Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
US9597309B2 (en)	2013-03-14	2017-03-21	Zafgen, Inc.	Methods of treating renal disease and other disorders
AR105671A1 (es)	2015-08-11	2017-10-25	Zafgen Inc	Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh)	2015-08-11	2017-02-22	扎夫根公司	烟曲霉素醇螺环化合物和制备和使用其的方法
CN113321753B (zh) *	2021-05-19	2022-08-30	山东滨州智源生物科技有限公司	多元糖基氨基酸基环糊精衍生物、水凝胶的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0764884B2 (ja) *	1986-11-27	1995-07-12	株式会社トクヤマ	シクロデキストリン組成物
ES2059571T3 (es) *	1988-01-19	1994-11-16	Takeda Chemical Industries Ltd	Fumagilina como agente angiostatico.
DE68906942T3 (de) *	1988-03-29	1999-05-12	University Of Florida, Gainesville, Fla.	Pharmazeutische Zusammensetzungen für die parenterale Anwendung.
US5227372A (en) *	1990-03-07	1993-07-13	Children's Medical Center Corporation	Method for retaining ophthalmological agents in ocular tissues
TW282399B (de) *	1990-05-25	1996-08-01	Takeda Pharm Industry Co Ltd
DE69231457T2 (de) *	1991-06-21	2001-05-23	Takeda Chemical Industries Ltd	Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate

1993
- 1993-01-28 AT AT93101237T patent/ATE205092T1/de active
- 1993-01-28 EP EP93101237A patent/EP0555693B1/de not_active Expired - Lifetime
- 1993-01-28 DE DE69330690T patent/DE69330690T2/de not_active Expired - Fee Related
- 1993-01-29 CA CA002088428A patent/CA2088428A1/en not_active Abandoned
- 1993-01-29 US US08/011,457 patent/US5536623A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2088428A1 (en)	1993-07-31
DE69330690D1 (de)	2001-10-11
EP0555693B1 (de)	2001-09-05
EP0555693A1 (de)	1993-08-18
DE69330690T2 (de)	2002-06-20
US5536623A (en)	1996-07-16

Publication	Publication Date	Title
ATE205092T1 (de)	2001-09-15	Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe
DE69124715D1 (de)	1997-03-27	Zyklodextrinkomplex
ATE71090T1 (de)	1992-01-15	Heterocyclische verbindungen und deren herstellung und verwendung.
DE68923274D1 (de)	1995-08-03	Verfahren zur herstellung eines mit metall-radionuklid-markierten proteins.
JP3673888B2 (ja)	2005-07-20	ポルフィリン類金属錯体の製造方法
ATE145209T1 (de)	1996-11-15	Tri-aza-makrocyclen und verfahren zu ihrer herstellung
KR910004630A (ko)	1991-03-29	4-메틸렌-2-옥소-8-아자스피로[4,5]데칸 유도체들과 그 화합물들을 함유하는 약제학적 조성물 및 그것들을 제조하는 방법
ATE138571T1 (de)	1996-06-15	Verwendung von dioxabicyclo (3.3.0>octane derivaten zur herstellung eines arzneimittels zur hemmung des cholesterinmetabolismus.
Lydon et al.	1982	Synthesis and characterization of coordinated disulfides. Single-crystal structural analysis of [(en) 2Co (S (SC (CH3) 2COOH) C (CH3) 2COO)](ClO4) 2. cntdot. H2O
Derek	1994	Kinetics of aminolysis of some benzoyl fluorides and benzoic anhydrides in non-hydroxylic solvents
DE69013528D1 (de)	1994-12-01	Eine Perfluoralkylgruppe enthaltende Verbindung.
DE3885115D1 (de)	1993-12-02	Verfahren zur Herstellung von Thiolen.
ATE122343T1 (de)	1995-05-15	Triazolyl-hydrazidderivate und verfahren zu ihrer herstellung.
RO92245A (ro)	1987-07-30	Procedeu pentru prepararea unor derivati de 1,6-naftiridina
KR880001645A (ko)	1988-04-25	치료적으로 유용한 프리스티나마이신의 제조방법
ATE215934T1 (de)	2002-04-15	Neue histidinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel gegen freie radikale
HU895522D0 (en)	1990-09-28	Process for the preparation of new thienyl-oxy-alkyl-amine derivatives and pharmaceutical compositions containing them
KR890000406A (ko)	1989-03-14	신나모일아미드 유도체, 그들의 제조방법, 그들을 함유하는 제약학적 조성물 및 그들의 사용
Santos et al.	1993	Siderophore analogues. Chelating properties of a new cyclic diazadihydroxamic acid
KR900014305A (ko)	1990-10-23	소염제로서의 나프탈렌메탄아미노 유도체의 용도 및 이를 함유한 약학 조성물
SE9802643L (sv)	1998-09-30	2,3-Disubstituerade cyklopentanonderivat, förfarande för framställning av den och medicinsk användning därav
KR910006238A (ko)	1991-04-27	피라즐-3-카르복스아미드
AR008257A1 (es)	1999-12-29	Poliamidas estables a la intemperie y procedimiento para su elaboracion y aplicacion
IL106692A (en)	1997-04-15	AZIDOALKYL DERIVATIVES AND THEIR USE FOR THE PREPARATION OF 99mTc COMPLEXES FOR IMAGING
MATSUSHIMA et al.	1968	Nuclear Magnetic Resonance Studies on Schiff Base and Related Compounds derived from Pyridoxal